info@cliantha.com
Request a Proposal
Participate in Study
Cliantha Academy
Assay List
Career
About Us
Overview
Our Team
Services
Clinical Research
Early Phase (BA-BE / Phase-I)
Late Phase (Patient-based Clinical Trials)
Consumer Clinical Research
Lab Services
Small Molecule
Large Molecule
IVRT/IVPT
Veterinary Therapeutics (Preclinical-Bioanalytical)
Clinical Reference Lab
Biometric Solutions
Biostatistics & Programming
Data Management
Expertise
Core Therapeutics
Oncology
Dermatology
Respiratory
Others
Biosimilars
Vaccines
Allergy Testing
(Environmental Exposure Chamber)
Anti-perspirant Testing
(Humidity Chambers)
eClinical
Resource Hub
Research Papers
Brochures and Flyers
Blogs
News & Events
News
Upcoming Events
Media
Contact us
Dermatology Research Papers
Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W. Effect of Therapeutic Integrin (CD11a) Blockade with Efalizumab on Immune Responses to Model Antigens in Humans: Results of a Randomized, Single Blind Study. J Invest Dermatol 2008; 128:2615-2624.
Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48:535-541
Papp K, Bissonnette R, Krueger J, Carey W, Gratton D, Gulliver W, Lui H, Lynde C, Magee A, Patel P, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monocolonal antibody. J Am Acad Dermatol 2001; 45:665-674
Patel P, Danzig M. Comparative efficacy and safety of Loratadine and Cetirizine in patients with chronic idiopathic urticaria. Adv Ther 1997; 14:318-322.
Sadoway T, Nelson V, Zizek W, Tenorio N, Patel P, Lee F, Salapatek AM. Allergic phenotyping and prevalence of skin prick test positive subjects in New Jersey, USA consistent with a more northern clinical site located in the Greater Toronto Area (GTA), Canada. Allergy 2016; 71(S102): 484-485.
Pozza L, Salapatek AM, Soong F, Wilson D, Patel D, Patel P: Nasal spray antihistamine (Livostin®) prophylactic treatment improves ocular redness symptoms in a Conjunctival Allergen Challenge model. Ann Allergy Asthma Immunol 2009; 102:A119.
